MDI-2517 is under clinical development by MDI Therapeutics and currently in Phase I for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease). According to GlobalData, Phase I drugs for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MDI-2517’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MDI-2517 overview
MDI-2517 is under development for the treatment of other fibrosis, systemic sclerosis and interstitial lung disease. The drug candidate is adminstered through oral route as a tablet. It acts by targeting plasminogen activator inhibitor 1 (SERPINE1).
It was under development for the treatment of scleroderma, ARDS and Bronchiectasis, arterial thrombosis, venous thrombosis, idiopathic pulmonary fibrosis.
MDI Therapeutics overview
MDI Therapeutics Inc specialises in drug development and manufacturing of novel therapies for fibrotic diseases. The company is headquartered in United States.
For a complete picture of MDI-2517’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
